Current treatments in infantile colic are insufficient, with inadequate efficacy or intolerable
side-effects. Nepadutant, a tachykinin NK₂ receptor antagonist, was considered a promising
candidate through its mechanism of action and for its potential to be dosed orally in infants.
In a new publication the pharmacokinetics and exposure–response (duration
of crying and fussing) following treatment with nepadutant were described in infants (4-20
weeks) with colic.
Read more about this publication here